Postmortem of Rumored AZ-BMS Merger; China as the Bogeyman for US Biopharma's ROI Crisis; Forte Biosciences' Little Known Proxy War
Asian Biotechies In A Bar; Issue 149; 2026-08-09
iSWT Community
This is the newsletter of InScienceWeTrust community that publishes weekly. We aim to share the latest news in the biotech industry, particularly in the interface of EastWest biotech collaboration space.
Subscribe:.rss.atom.json.md.m3u.pls
Failing Last read · last published · next check
Last read successfully 6 days ago; attempts since then have failed.
Latest episodes
Saves to your Listen queue, to pick up on another day or another device.
“A Fatal Reaction" That is Preventable; Jaw-Dropping TCE Data for Multiple Myeloma; China's PIONEER Program as a New R&D Accelerator
Asian Biotechies In A Bar; Issue 148; 2026-07-06
BioVerse #33 - The West-East Biotech Relay - Accelerating Affordable Innovation
A joint webinar with China Pharmaceutical Innovation Conference (CPIC)
The Great Rebalancing of Biotech R&D; Biggest Clinical Surprise of 2026 from AstraZeneca & Ionis; Summary of the first China BioPioneers-BioVerse Webinar
Asian Biotechies In A Bar; Issue 147; 2026-07-12
BioVerse #32 & China BioPioneers International Edition: Innovation, Globalization, and the Next Wave of ADC Development: China–West Perspectives.
We are proud to announce our collaboration with Healthcare Executive, Weijieyao and sponsor Asymchem Group on the inaugural episode of China BioPionners International Edition — a milestone that sits at the heart of our community's mission: bridging the Eastern and Western biopharma worlds to foster deeper understanding and meaningful collaboration.
A Trans-Pacific Biotech Relay Model; Pfizer ADC's Phase 3 Flop and A BioTwitter Debate Over a Newco; A Communication Guidebook for Asian Biotechs
Asian Biotechies In A Bar; Issue 146; 2026-06-28
A China CRO Selection Framework for Western Biotechs; Return to Normalcy at the FDA; Recap of the China Biotech panel from SAPA-NE Annual Conference
Asian Biotechies In A Bar; Issue 145; 2026-06-21
Conversation with Eli Lilly's Top Deal-Maker; Recap of Biotech Deal-Making Panel; Tango's Latest PRMT5 Data
Asian Biotechies In A Bar; Issue 144; 2026-06-14
BioVerse #31 - ASCO & ADA 2026 Recap - Asian Biotech On the Rise
BioVerse - Where Science Sparks Business in Medicines
Divergent Reception of China-Only Data from Akeso and Legend; Post-Daraxonrasib Landscape of KRAS
Asian Biotechies In A Bar; Issue 143; 2026-06-07
Pfizer-Innovent $10.5-billion deal & China biotech moments at ASCO 2026; The untold Kelun story behind its SAC-TMT
Asian Biotechies In A Bar; Issue 142; 2026-05-31
Memorial Day Weekend Listening & Reading; Boston Chapter Career Developemnet Event; ASCO 2026 Networking
Asian Biotechies In A Bar; Issue 141; 2026-05-24
Lessons from Neurona's $1.15B Exit; Reflections on UChicago China Forum; A Clean Slate of FDA Leadership
Asian Biotechies In A Bar; Issue 140; 2026-05-17
How Candid Therapeutics Leveraged Clinical Trials in China for a $2.2-Billion Acquisition; Marty Makary Allegedly Being Fired; Next-Gen CDK to Watch at ASCO
Issue 139; 2026-05-10
Sun Pharma to Acquire Organon for $11.75 Bn; A Bad Week for China Biotech; US and Europe's Diverging Attitudes toward China Biotech
Issue 138; 2026-05-03
BioVerse #30 - Recap of AACR2026 - ADC, (K)RAS, Synthetic Lethality, Immuno-Oncology, New Drugs, and AI
BioVerse #30
China to Close Drug Pricing Gap; PD-1xVEGF & TROP2 Preview at ASCO; Three Near-Deaths and One 70x Return Behind Kelonia's $7-Billion Acquisition
Issue 137; 2026-04-26
RAS is On; China Newco After Kailera's IPO Success
Issue 136; 2026-04-19
FDA Answers to China's IIT; Biotech's "Three-Body Problem"; Breaking In, Moving Up - A Career Tip for East Asian Biopharma Exe
Issue 135; 2026-04-12
Western Companies' New China Strategies; Why MFN Matters to Asian Biotech; Decode The New Tariffs for Patented Pharmaceuticals
Issue 134; 2026-04-05